1. Short title This Act may be cited as the Access to Innovative Treatments Act of 2023 . 2. Providing a review process for adverse national coverage determinations with respect to drug coverage under the Medicare program (a) In general Section 1862(l) of the Social Security Act ( 42 U.S.C. 1395y(l) ) is amended— (1) by redesignating paragraphs (5) and (6) as paragraphs (7) and (8), respectively; and (2) by inserting after paragraph (4) the following new paragraphs: (5) Review of national coverage determinations for drugs and biologicals (A) In general Subject to subparagraph (D), not later than 30 days after receiving a request for a review of a specified national coverage determination (as defined in subparagraph (E)), the Secretary shall initiate such a review in accordance with the provisions of this paragraph. (B) Public comment period Beginning on the date of the initiation of a review of a specified national coverage determination under subparagraph (A), the Secretary shall provide for a 30-day public comment period as to whether such determination should be affirmed, reversed, or otherwise modified. (C) Final decision Not later than 30 days after the conclusion of the 30-day period described in subparagraph (B) with respect to a specified national coverage determination, the Secretary shall— (i) make a final decision as to whether such determination should be affirmed, reversed, or otherwise modified; (ii) include in such final decision summaries of the public comments received and responses to such comments; (iii) make available to the public the clinical evidence and other data used in making such decision when such decision differs from the recommendations of the Medicare Coverage Advisory Committee